Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Wharton's Jelly Allograft for Knee Osteoarthritis
NCT06608134Phase 1Recruiting
- Sponsor
- R3 Stem Cell
- Start
- Oct 2024
- Primary completion
- Oct 2028
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GeneXSTEM in osteoarthritis (OA) (3 arms), sponsored by R3 Stem Cell. Primary endpoints: C Reactive Protein at 1 year, Erythrocyte Sedimentation Rate at 1 year and 3 more. Started Oct 2024; status: recruiting.
02
Drugs
GeneXSTEM
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06608134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06608134.